<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8610688</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5937</journal-id>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov. Disord.</journal-id>
<journal-title-group>
<journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30537011</article-id>
<article-id pub-id-type="pmc">6413690</article-id>
<article-id pub-id-type="doi">10.1002/mds.27553</article-id>
<article-id pub-id-type="manuscript">NIHMS1016183</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Microglial Cell Activation and Senescence are Characteristic of the Pathology FXTAS</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cerdeño</surname>
<given-names>Verónica Martínez</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hong</surname>
<given-names>Tiffany</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Amina</surname>
<given-names>Sarwat</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lechpammer</surname>
<given-names>Mirna</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ariza</surname>
<given-names>Jeanelle</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Noctor</surname>
<given-names>Stephen C.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Paul</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Pathology and Laboratory Medicine, UC Davis School of Medicine, Sacramento, California, USA</aff>
<aff id="A2"><label>2</label>Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children of Northern California, Sacramento, California, USA</aff>
<aff id="A3"><label>3</label>MIND Institute, UC Davis Medical Center, Sacramento, California, USA</aff>
<aff id="A4"><label>4</label>Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine Sacramento, California, USA</aff>
<aff id="A5"><label>5</label>Department of Psychiatry and Behavioral Sciences, UC Davis School of Medicine Sacramento, California, USA</aff>
<aff id="A6"><label>6</label>Department of Pediatrics, UC Davis School of Medicine Sacramento, California, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label><bold>Correspondence to:</bold> Dr. Verónica Martínez-Cerdeño, Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children of Northern California, 2425 Stockton Boulevard, Sacramento, CA 95817, USA; <email>vmartinezcerdeno@ucdavis.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P32"><bold>Relevant conflicts of interest/financial disclosures:</bold> Nothing to report.</p>
<p id="P33">Full financial disclosures and author roles may be found in the online version of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>33</volume>
<issue>12</issue>
<fpage>1887</fpage>
<lpage>1894</lpage>
<!--elocation-id from pubmed: 10.1002/mds.27553-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P1">Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with premutation alleles of the <italic>FMR1</italic> gene. Expansions of more than 200 CGG repeats give rise to fragile X syndrome, the most common inherited form of cognitive impairment. Fragile X-associated tremor/ataxia syndrome is characterized by cerebellar tremor and ataxia, and the presence of ubiquitin-positive inclusions in neurons and astrocytes. It has been previously suggested that fragile X-associated tremor/ataxia syndrome is associated with an inflammatory state based on signs of oxidative stress–mediated damage and iron deposition.</p>
</sec>
<sec id="S2">
<title>Objective:</title>
<p id="P2">Determine whether the pathology of fragile X-associated tremor/ataxia syndrome involves microglial activation and an inflammatory state.</p>
</sec>
<sec id="S3">
<title>Methods:</title>
<p id="P3">Using ionized calcium binding adaptor molecule 1 and cluster differentiation 68 antibodies to label microglia, we examined the number and state of activation of microglial cells in the putamen of 13 fragile X-associated tremor/ataxia syndrome and 9 control postmortem cases.</p>
</sec>
<sec id="S4">
<title>Results:</title>
<p id="P4">Nearly half of fragile X-associated tremor/ataxia syndrome cases (6 of 13) presented with dystrophic senescent microglial cells. In the remaining fragile X-associated tremor/ataxia syndrome cases (7 of 13), the number of microglial cells and their activation state were increased compared to controls.</p>
</sec>
<sec id="S5">
<title>Conclusions:</title>
<p id="P5">The presence of senescent microglial cells in half of fragile X-associated tremor/ataxia syndrome cases suggests that this indicator could be used, together with the presence of intranuclear inclusions and the presence of iron deposits, as a biomarker to aid in the postmortem diagnosis of fragile X-associated tremor/ataxia syndrome. An increased number and activation indicate that microglial cells play a role in the inflammatory state present in the fragile X-associated tremor/ataxia syndrome brain. Anti-inflammatory treatment of patients with fragile X-associated tremor/ataxia syndrome may be indicated to slow neurodegeneration.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>